Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2010 - 2026)

Neuroone Medical Technologies' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 69.83% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 77.79% YoY) and the FY2025 annual result came in at $10.8 million, up 100.85% from the prior year.
• Liabilities and Shareholders Equity was $7.6 million for Q1 2026 at Neuroone Medical Technologies, down from $8.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.1 million in Q1 2022 and bottomed at $4.5 million in Q1 2025.
• A 5-year average of $8.2 million and a median of $7.6 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 50.24% — and 2025, when it soared 120.24%.
• Neuroone Medical Technologies' Liabilities and Shareholders Equity stood at $9.7 million in 2022, then sank by 39.73% to $5.8 million in 2023, then advanced by 11.54% to $6.5 million in 2024, then jumped by 32.08% to $8.6 million in 2025, then decreased by 11.76% to $7.6 million in 2026.
• Business Quant data shows NMTC's Liabilities and Shareholders Equity at $7.6 million in Q1 2026, $8.6 million in Q4 2025, and $10.8 million in Q3 2025.